Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Recruiting 2Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 277Lymphoid 231Myeloid 140Plasma cell 89Dermatologic 64Classical hematology 58Sarcoma 34Genitourinary 18Gynecologic 11Head & Neck 7Gastrointestinal 7Breast 6Thoracic 4Other neoplasm 3Tumor-Agnostic 2CNS 2Other solid neoplasm 1Other 1

Conditions

Mesothelioma, Malignant 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × fludarabine phosphate × Other solid neoplasm × Clear all
NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

University Health Network, Toronto

Phase 1/2 Completed
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡